MedTrace Logo

SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access

NCT02507947 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-07-09

No results posted yet for this study

Summary

SPECTAmel is a standardized, quality-assured molecular screening platform for tumor characterization and storage of human biological material (HBM) for the purpose of integrating new biomarkers into clinical trials and optimizing access of patients to therapeutic biomarker-driven clinical trials. HBM and clinical/pathological data are collected from consenting patients.

Conditions

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Caroline Robert, MD, PhD · Gustave Roussy, Cancer Campus, Grand Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2030-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02507947 on ClinicalTrials.gov